leisure time -WSS

leisure time

author：comprehensive 2025-09-30 12:17:21 - browse：86665

illustration of one blue dna strand — Adobe

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made by Vertex Pharmaceuticals and CRISPR Therapeutics.

Tuesday’s meeting is set up a bit differently than most FDA advisory panels. The agency has not raised any concerns about exa-cel’s efficacy or safety, and there will not be a typical vote at the end of the day on whether the data from exa-cel’s pivotal clinical trial support an approval as a treatment for sickle cell disease.

Instead, the FDA is seeking input about the methods used by Vertex and CRISPR Therapeutics to evaluate the risk of inadvertently making unwanted changes to patients’ DNA — so-called off-target editing — when exa-cel is administered.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Future doctors need a strong humanities education

knowledge

hotspot

WSS

Beach reads and more: STAT's 2023 summer book list

Palantir health business leans on meeting customers’ needs

Oak trusses raised to roof of fire

Mass General, Mayo Clinic look to monetize custom

Printout prescription drug information shouldn’t go digital

Retired US general questions alleged Putin, Prigozhin meeting

knowledge

leisure time

focus

Malaria cases in Florida and Texas: Here’s what you need to know

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Guidelines to prevent youth baseball injuries need more muscle

Pumping milk in bathrooms at health conferences is common

Dobbs anniversary: the lost opportunity of abortion as health care

Pumping milk in bathrooms at health conferences is common

Sports medicine is finally prioritizing gender equality

N.Y. state detects polio case, first in the U.S. since 2013

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

California’s proposed $25 per hour health care minimum wage

focus

Maisha Meds is a PBM, but don't call it that

Head of FDA's diagnostics center, who led through Covid, retires

Dog Aging Project founders on what lies ahead after losing funding

Lecanemab for Alzheimer's is coming. Is the health system ready?

It's time to get medical device identifiers over the finish line

Living with Fabry disease, a condition that causes chronic pain

knowledge

hotspot

knowledge

leisure time